Chlordiazepoxide
Chlordiazepoxide, trade name Librium among others, is a sedative and hypnotic medication of the benzodiazepine class; it is used to treat anxiety, insomnia and symptoms of withdrawal from alcohol and other drugs.
Clinical data | |
---|---|
Pronunciation | /ˌklɔːrdaɪ.əzɪˈpɒksaɪd/ |
Trade names | Librium, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682078 |
Dependence liability | High |
Routes of administration | By mouth intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 5–30 hours (Active metabolite desmethyldiazepam 36–200 hours: other active metabolites include oxazepam) |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.337 |
Chemical and physical data | |
Formula | C16H14ClN3O |
Molar mass | 299.76 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Chlordiazepoxide has a medium to long half-life but its active metabolite has a very long half-life. The drug has amnesic, anticonvulsant, anxiolytic, hypnotic, sedative and skeletal muscle relaxant properties.
Chlordiazepoxide was patented in 1958 and approved for medical use in 1960. It was the first benzodiazepine to be synthesized and the discovery of chlordiazepoxide was by pure chance. Chlordiazepoxide and other benzodiazepines were initially accepted with widespread public approval but were followed with widespread public disapproval and recommendations for more restrictive medical guidelines for its use.